Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s stock finished Thursday's session 0.47% lower at $25.21 with a total trading volume of 439,608 shares. The Company's shares have advanced 7.60% in the past month, 8.95% over the previous three months, and 9.70% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 8.90% and 16.88%, respectively. Furthermore, shares of Wright Medical Group, which designs, manufactures, markets, and sells orthopedic products in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 67.79.
As per a SEC filing dated December 29th, 2016, Wright Medical on December 23rd, 2016, entered into a Credit, Security and Guaranty Agreement by and among the Company, as a guarantor, and certain of its other wholly-owned US subsidiaries, as borrowers, Midcap Financial Trust, as administrative agent and a lender and the additional lenders from time to time party thereto. The Credit Agreement provides for a $150.0 million senior secured asset based line of credit, subject to the satisfaction of a borrowing base requirement (ABL Facility). The ABL Facility may be increased by up to $100.0 million upon the Borrowers' request, subject to the consent of the Agent and each of the other lenders providing such increase.
On January 03rd, 2017, research firm Guggenheim downgraded the Company's stock rating from 'Buy' to 'Neutral'. Your complete research report on WMGI can be retrieved for free at:
Varian Medical Systems
Shares in Palo Alto, California headquartered Varian Medical Systems Inc. ended at $90.15, up 0.04% from the last trading session. The stock recorded a trading volume of 628,343 shares. The Company's shares have gained 0.41% since the start of this year. The stock is trading 0.03% above its 50-day moving average and 1.05% above its 200-day moving average. Moreover, shares of Varian Medical Systems, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 51.59.
On January 10th, 2017, Varian Medical Systems announced that its Board of Directors approved the previously announced separation of the company's Imaging Components business. The separation is intended to be executed via a tax-free distribution to Varian stockholders of common stock in Varex Imaging Corporation, a new stand-alone public company that will hold the Imaging Components business. The distribution is expected to be completed on January 28, 2017. In the distribution, Varian's stockholders would receive 0.4 share of Varex's common stock for every one share of Varian common stock held as of January 20th, 2017, the record date for the distribution. VAR free report is just a click away at:
Marietta, Georgia headquartered MiMedx Group Inc.'s stock ended yesterday's session 1.05% lower at $8.49 with a total trading volume of 600,798 shares. The Company's shares have advanced 1.68% in the previous three months. The stock is trading 2.96% above its 200-day moving average. Additionally, shares of MiMedx Group, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone, have an RSI of 38.65.
On January 09th, 2017, MiMedx announced that Q4 2016 revenue grew 38% compared to Q4 2015 revenue. Q4 2016 revenue of $71.6 million was in the upper range of MiMedx's Q4 2016 guidance. Full year 2016 revenue is a 32% increase over full year 2015 revenue. Sign up for your complimentary research report on MDXG at:
At the close on Thursday, shares in San Diego, California headquartered NuVasive Inc. recorded a trading volume of 533,043 shares. The stock finished 1.13% lower at $69.89. The Company's shares have gained 3.62% in the last one month, 5.80% over the previous three months, and 3.76% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.35% and 14.85%, respectively. Furthermore, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 66.54. Register for free on Stock-Callers.com and download the latest research report on NUVA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA